



US009636387B2

(12) **United States Patent**
Abdul-Wahid et al.

(10) **Patent No.:** US 9,636,387 B2
(45) **Date of Patent:** *May 2, 2017

(54) **N-DOMAIN OF CARCINOEMBRYONIC ANTIGEN AND COMPOSITIONS, METHODS AND USES THEREOF**

5,672,513 A 9/1997 Terskikh et al.
2005/0063952 A1 3/2005 Klysner et al.
2005/0147614 A1 * 7/2005 Begent et al. 424/155.1

(71) Applicant: **Governing Council of the University of Toronto**, Toronto (CA)

FOREIGN PATENT DOCUMENTS

CN 1634982 A 7/2005
WO 2009002418 A 12/2008

(72) Inventors: **Aws Abdul-Wahid**, Montreal (CA); **Jean Gariépy**, Toronto (CA)

OTHER PUBLICATIONS

(73) Assignee: **Governing Council of the University of Toronto**, Toronto (CA)

Bowie et al. (Science, 1990, 247:1306-1310).^{*}
Burgess et al. (J. Cell Biol. 111:2129-2138, 1990).^{*}
Lazar et al. (Mol. Cell. Biol., 8:1247-1252, 1988).^{*}
Bork (Genome Research, 2000,10:398-400).^{*}
Vajdos et al. (J Mol Biol. Jul. 5, 2002;320(2):415-28 at 416).^{*}
Brown et al. (J Immunol. May 1996;156(9):3285-91.^{*}
Sporn et al., "Chemoprevention of Cancer," Carcinogenesis, vol. 21 (2000), 525-530.^{*}

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

Auerbach et al (Cancer and Metastasis Reviews, 2000, 19: 167-172).^{*}

This patent is subject to a terminal disclaimer.

Gura T (Science, 1997, 278(5340): 1041-1042, encloses 1-5).^{*}

(21) Appl. No.: **14/461,585**

Jain RK (Scientific American, Jul. 1994,58-65).^{*}

(22) Filed: **Aug. 18, 2014**

Sainz-Pastor et al (Int J Biol Macromol. Aug. 15, 2006;39(1-3):141-50. Epub Mar. 28, 2006).^{*}

(65) **Prior Publication Data**

US 2015/0044218 A1 Feb. 12, 2015

Related U.S. Application Data

(63) Continuation of application No. 13/697,295, filed as application No. PCT/CA2011/000540 on May 11, 2011, now Pat. No. 8,846,050.

Hefta, Laura J.F. et al., Expression of Carcinoembryonic Antigen and Its Predicted Immunoglobulin-like Domains in HeLa Cells for Epitope Analysis, Cancer Research, vol. 52, pp. 5647-5655. Oct. 15, 1992.

(60) Provisional application No. 61/333,587, filed on May 11, 2010.

Aurisicchio, L. et al. "Patented cancer vaccines: the promising leads." Expert Opin. Ther. Patents (2010) 20(5), pp. 1-14.

(51) **Int. Cl.**

A61K 39/00 (2006.01)
A61K 39/395 (2006.01)
C07K 16/18 (2006.01)
C07K 14/435 (2006.01)
C07K 16/30 (2006.01)
A61K 31/711 (2006.01)
A61K 48/00 (2006.01)

Hallermalm, K. "T-cell epitope analogues from carcinoembryonic antigen for vaccination against cancer: WO2009002418". Expert Opin. Ther. Patents (2009) 19(11), pp. 1635-1637.

(52) **U.S. Cl.**

CPC **A61K 39/0011** (2013.01); **A61K 31/711** (2013.01); **A61K 39/3958** (2013.01); **C07K 14/435** (2013.01); **C07K 16/18** (2013.01); **C07K 16/3007** (2013.01); **A61K 48/00** (2013.01); **A61K 2039/505** (2013.01); **A61K 2039/53** (2013.01); **A61K 2039/55561** (2013.01); **A61K 2039/575** (2013.01); **C07K 2317/732** (2013.01); **C07K 2317/734** (2013.01); **C07K 2317/76** (2013.01)

Abdul-Wahid, Aws and Gariépy, Jean, Overcoming Immunological Anergy Against the Human Carcinoembryonic Antigen Results in Delayed Tumor Growth. Poster and Abstract. CI 2010.org—14th International Congress of Immunology. Aug. 22-27, 2010—Kobe, Japan.

(58) **Field of Classification Search**

Abdul-Wahid, Aws et al., Overcoming Immunological Anergy Against the Human Carcinoembryonic Antigen (CEA) Results in Delayed Tumor Growth. p. 42, 20th Annual International CEA Symposium, McGill University, Montreal, Quebec, Aug. 8-11, 2010.

None

Hodge, James W., "Carcinoembryonic antigen as a target for cancer vaccines", Cancer Immunology and Immunotherapy, Springer-Verlag, 1996, vol. 43: pp. 127-134.

See application file for complete search history.

Hashino, J. et al., "Production and Characterization of Monoclonal Antibodies to N-Domain and Domain III of Carcinoembryonic Antigen", Biochemical and Biophysical Research Communications, Dec. 15, 1993, vol. 197, No. 2, pp. 886-893.

(56) **References Cited**

Blumenthal, R.D. et al., "Inhibition of Adhesion, Invasion, and Metastasis by Antibodies Targeting CEACAM6 (MCA-90) and CEACAM5 (Carcinoembryonic Antigen)", Cancer Research, Oct. 1, 2005, vol. 65, No. 19, pp. 8809-8817.

* cited by examiner

Primary Examiner — Brian J Gangle

Assistant Examiner — Andrea McCollum

(74) *Attorney, Agent, or Firm* — Bereskin & Parr LLP;
Melanie Szweras

(57) **ABSTRACT**

The present disclosure provides immunogenic compositions comprising the N-domain of carcinoembryonic antigen (CEA). These compositions are useful for inducing or enhancing an immune response, for inhibiting tumor cell growth and for treating cancer.

5,595,756 A * 1/1997 Bally et al. 424/450
5,648,078 A 7/1997 Hashino et al.